A Relative Bioavailability Study of Mirtazapine 15 mg Tablets Under Non-fasting Conditions
Status:
Completed
Trial end date:
2001-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to compare the relative bioavailability of 15 mg Mirtazapine
Tablets by Purepac Pharmaceutical Co with that of 15 mg REMERON® Tablets by Organon Inc.
following a single oral dose (1 x 15 mg) in healthy adult volunteers under non-fasting
conditions.